Drugmaker GSK reviewing its R&D programs under new CEO

Drugmaker GSK reviewing its R&D programs under new CEO


Drugmaker GlaxoSmithKline says it will halt some 30 clinical and pre-clinical programs as it reviews its research and development pipeline and focuses on improving efficiency. London-based GSK says it will also undertake a strategic review of its Rare Diseases unit and "is now considering options for future ownership of these assets."



from Biotech News